TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11018096

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens from phase II studies with expected power of 0.62 and 0.58
Number of subjects: 21

Group type: COMPARATOR
Intervention: Chemotherapy regimens from six other phase II studies
Number of subjects: 21
Study: 9346990

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) therapy
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 5
Study: 8358664

Group type: EXPERIMENTAL
Intervention: Prosol (0.12% chlorhexidine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 0
Study: 3003020

Group type: EXPERIMENTAL
Intervention: Atenolol, 50 mg once/day
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ICI 118551, 20 mg 3 times/day
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 30208956

Group type: EXPERIMENTAL
Intervention: Shaping the Social intervention
Number of subjects: 10190

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 10190
Study: 26059831

Group type: EXPERIMENTAL
Intervention: Voice Training Program
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Both Groups
Number of subjects: 204
Study: 23803593

Group type: EXPERIMENTAL
Intervention: Visit-to-visit blood pressure variability (VTV-BPV) measured by the coefficient of variation (CV) and average real variability in systolic blood pressure (SBP).
Number of subjects: 1844
Study: 22463944

Group type: EXPERIMENTAL
Intervention: Herbal treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 20144188

Group type: EXPERIMENTAL
Intervention: Patient-guided focussed medium-energy density ESWT treatments (3 sessions at weekly intervals)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 18953177

Group type: EXPERIMENTAL
Intervention: P-APC-PCI complex level in patients with frequent AVFG failures (n = 8)
Number of subjects: 35

Group type: COMPARATOR
Intervention: P-APC-PCI complex level in patients with less frequent AVFG failures (n = 27)
Number of subjects: 35
Study: 16167962

Group type: EXPERIMENTAL
Intervention: 6 hours administration of misoprostol
Number of subjects: 450

Group type: COMPARATOR
Intervention: 36-48 hours administration of misoprostol
Number of subjects: 450
Study: 12870373

Group type: EXPERIMENTAL
Intervention: Magnesium flush infusion into the aortic root before cross-clamp removal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo flush infusion into the aortic root before cross-clamp removal
Number of subjects: 0
Study: 10385632

Group type: EXPERIMENTAL
Intervention: UDCA therapy (600 mg/d)
Number of subjects: 527
Study: 8874423

Group type: EXPERIMENTAL
Intervention: One-ring treatment group (17 eyes)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Two-ring treatment group (8 eyes)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 28
Study: 1997518

Group type: EXPERIMENTAL
Intervention: Pergolide (50 micrograms/day in trial I; 75-100 micrograms/day in trial II)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Bromocriptine (5 mg/day in trial I; 7.5-10 mg/day in trial II)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 157

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 157
Study: 6662933

Group type: EXPERIMENTAL
Intervention: Depressed male case history
Number of subjects: 90

Group type: COMPARATOR
Intervention: Depressed female case history
Number of subjects: 90
Study: 31446992

Group type: EXPERIMENTAL
Intervention: Afatinib starting dose of 20 mg/day, with potential increase in 10 mg increments up to 50 mg/day
Number of subjects: 46
Study: 30559773

Group type: EXPERIMENTAL
Intervention: Endoscopic stapedotomy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Microscopic stapedotomy
Number of subjects: 42
Study: 26844688

Group type: EXPERIMENTAL
Intervention: Vitamin-D and calcium replacement (800 IU Vitamin-D and 500 mg Calcium once daily)
Number of subjects: 87

Group type: COMPARATOR
Intervention: No vitamin-D and calcium replacement
Number of subjects: 87
Study: 24418213

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 80

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 80
Study: 22008377

Group type: EXPERIMENTAL
Intervention: Zopiclone 5 or 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ethanol 50 g
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19887218

Group type: EXPERIMENTAL
Intervention: Surface electrical stimulation program (frequency 45 Hz, impulse 200 micros, 10s on/10s off) for 8 weeks on the biceps brachii of both arms.
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 30
Study: 17258104

Group type: EXPERIMENTAL
Intervention: Structured nursing intervention program including music therapy, drama, and group therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 0
Study: 12825865

Group type: COMPARATOR
Intervention: Regular dose of omeprazole (20 mg/day for 3 days)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: High dose of omeprazole (80 mg bolus + 8 mg/h infusion/day for 3 days)
Number of subjects: 101
Study: 10806604

Group type: EXPERIMENTAL
Intervention: Tenecteplase (30, 40, or 50 mg intravenous bolus)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Alteplase (100 mg intravenous as accelerated 90-minute infusion)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Tenecteplase (approximately 0.5 mg/kg)
Number of subjects: 159
Study: 8932540

Group type: EXPERIMENTAL
Intervention: 120 mg verapamil
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 180 mg verapamil
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 360 mg verapamil
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 540 mg verapamil
Number of subjects: 48
Study: 1641292

Group type: EXPERIMENTAL
Intervention: Interferon gamma (1 million units/m2, three times a week for 24 weeks)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Interferons alfa and gamma (5 MU/m2 for 12 weeks followed by 1 MU/m2 of interferon gamma, three times a week)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 35
Study: 6679514

Group type: EXPERIMENTAL
Intervention: Lisuride (0.0250 mg single oral dose)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pizotiphene
Number of subjects: 45
Study: 30839426

Group type: EXPERIMENTAL
Intervention: Positive verbal suggestions regarding the benefits of acupuncture needling
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Positive treatment-related suggestions
Number of subjects: 96

Group type: COMPARATOR
Intervention: Neutral verbal suggestions regarding the benefits of acupuncture needling
Number of subjects: 96
Study: 28552083

Group type: EXPERIMENTAL
Intervention: Specialist Supportive Clinical Management
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Maudsley Model Anorexia Nervosa Treatment for Adults
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Enhanced Cognitive Behavioural Therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 26316741

Group type: EXPERIMENTAL
Intervention: Olodaterol 2 µg
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Olodaterol 5 µg
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Olodaterol 10 µg
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study: 23159168

Group type: EXPERIMENTAL
Intervention: Orthodontic treatment in conjunction with orthognathic surgery
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (age and gender matched subjects)
Number of subjects: 121
Study: 21529928

Group type: EXPERIMENTAL
Intervention: 380 mg XR‐NTX
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 19624833

Group type: EXPERIMENTAL
Intervention: Internet-based programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face-to-face group treatment programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 16449111

Group type: EXPERIMENTAL
Intervention: 4% intrauterine lidocaine infusion
Number of subjects: 80

Group type: COMPARATOR
Intervention: saline
Number of subjects: 80
Study: 16121931

Group type: EXPERIMENTAL
Intervention: Mitherapist (15 mg/dl Lentinan, particulate size of 0.2 microm)
Number of subjects: 0
Study: 10224992

Group type: EXPERIMENTAL
Intervention: Resource mothers program
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (phenylketonuric women without resource mothers)
Number of subjects: 83
Study: 9138755

Group type: EXPERIMENTAL
Intervention: Post-transplant patients
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Skin tumors
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Lymphoproliferative disorders
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Non-Hodgkin's lymphoma
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Gynecological tumors
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Miscellaneous tumors
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 690
Study: 1941003

Group type: EXPERIMENTAL
Intervention: General practice recruitment strategy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Local community approach
Number of subjects: 400

Group type: COMPARATOR
Intervention: Electoral roll recruitment strategy
Number of subjects: 400
Study: 6310996

Group type: EXPERIMENTAL
Intervention: Amdinocillin plus cefoxitin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cefoxitin alone
Number of subjects: 45
Study: 31953790

Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF) 462 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dimethyl fumarate (DMF) 240 mg
Number of subjects: 0
Study: 30565327

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham patch
Number of subjects: 10
Study: 29800295

Group type: EXPERIMENTAL
Intervention: Extended-pulsed fidaxomicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study: 26738971

Group type: EXPERIMENTAL
Intervention: Pen included with questionnaire
Number of subjects: 7625

Group type: COMPARATOR
Intervention: Control group (questionnaire alone)
Number of subjects: 7625
Study: 24888488

Group type: EXPERIMENTAL
Intervention: Siltuximab 15 mg/kg every 4 weeks + best supportive care (BSC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo + best supportive care (BSC)
Number of subjects: 76
Study: 22356258

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg (partial responders adjusted to dosing every 8 weeks)
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg (partial responders adjusted to dosing every 8 weeks)
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 766
Study: 20530973

Group type: EXPERIMENTAL
Intervention: Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil (E-CMF: Epirubicin 100 mg/m² on day 1, CMF: 600 mg/m² cyclophosphamide, 40 mg/m² methotrexate, 600 mg/m² 5-fluorouracil on days 1 and 8)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Paclitaxel followed by epirubicin and vinorelbine (T-EV: Paclitaxel 175 mg/m² on day 1, Epirubicin 75 mg/m² on day 1, Vinorelbine 25 mg/m² on days 1 and 8)
Number of subjects: 244
Study: 18613793

Group type: EXPERIMENTAL
Intervention: Carbapenems combined with thymosin alpha(1) and ulinastatin (CTU group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Carbapenems and placebo (CP group)
Number of subjects: 120
Study: 16485513

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/day for the first month and 8 mg/day for the remaining 11 months)
Number of subjects: 1252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1252
Study: 11920300

Group type: EXPERIMENTAL
Intervention: Combination B vaccine (recombinant Plasmodium falciparum ring‐infected erythrocyte surface antigen and 2 merozoite surface proteins (MSP1 and MSP2) formulated in oil‐based adjuvant)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination B vaccine
Number of subjects: 120
Study: 10325814

Group type: EXPERIMENTAL
Intervention: Trophic feeding (0.5 ml/h if birthweight < 1 kg, 1 ml/h if ≥ 1 kg) in addition to parenteral nutrition
Number of subjects: 70

Group type: COMPARATOR
Intervention: Parenteral nutrition alone
Number of subjects: 70
Study: 8949568

Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH) 0.5 U/kg/week
Number of subjects: 28
Study: 2021299

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Interpersonal psychotherapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Behavior therapy
Number of subjects: 75
Study: 31072023

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Beetroot juice (BRJ) with Vitamin C
Number of subjects: 29
Study: 28094031

Group type: EXPERIMENTAL
Intervention: Frequent in-center hemodialysis (six times per week)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Frequent nocturnal home hemodialysis (six times per week)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Conventional hemodialysis (three times per week)
Number of subjects: 332
Study: 25710276

Group type: EXPERIMENTAL
Intervention: Topical BAK-preserved tafluprost
Number of subjects: 195

Group type: COMPARATOR
Intervention: SofZia-preserved travoprost
Number of subjects: 195
Study: 23777776

Group type: EXPERIMENTAL
Intervention: Resident-initiated advanced triage
Number of subjects: 1346

Group type: COMPARATOR
Intervention: Control (patients evaluated during the 6-h period on other weekdays)
Number of subjects: 1346
Study: 21570522

Group type: EXPERIMENTAL
Intervention: 1 g/d n3-PUFA
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 4 g/d n3-PUFA
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 19770175

Group type: EXPERIMENTAL
Intervention: Occupational therapy home program (OTHP) for 8 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Occupational therapy home program (OTHP) for 4 weeks (continued for 8 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No occupational therapy home program (no OTHP)
Number of subjects: 36
Study: 17623345

Group type: EXPERIMENTAL
Intervention: Baseline viral load level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD4+ cell counts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD8 cell counts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient's age
Number of subjects: 0
Study: 15580811

Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C, 800 mg vitamin E, and 10 mg folate
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 11797982

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rtPA)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Urokinase (UK)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Both rtPA and UK (independent of delivery technique)
Number of subjects: 234
Study: 9740162

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at 0.2 IU/kg/d subcutaneously for 4 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (dietary prescriptions only)
Number of subjects: 17
Study: 7989939

Group type: EXPERIMENTAL
Intervention: Chemotherapy (adjuvant fluorouracil (5-FU)-based)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 294

Group type: COMPARATOR
Intervention: Low TS levels (no specific intervention mentioned)
Number of subjects: 294
Study: 2925972

Group type: EXPERIMENTAL
Intervention: Positive interactional context
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative interactional context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dissatisfied set
Number of subjects: 0

Group type: COMPARATOR
Intervention: Satisfied set
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Established negative sets regarding adolescent's behaviors
Number of subjects: 0
Study: 31999946

Group type: COMPARATOR
Intervention: TAS-102
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: TAS-102 plus bevacizumab
Number of subjects: 93
Study: 30997744

Group type: EXPERIMENTAL
Intervention: Distraction cards
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (family nearby, no distraction techniques)
Number of subjects: 60
Study: 28314744

Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 140

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 140
Study: 25533572

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block (SGB)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Follow-up observation (no treatment)
Number of subjects: 104
Study: 22959395

Group type: EXPERIMENTAL
Intervention: Low dose multidetector computed tomography coronary angiography (MDCT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 80
Study: 21982664

Group type: EXPERIMENTAL
Intervention: Anacetrapib (ANA) 150 mg
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Anacetrapib (ANA) 300 mg
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Anacetrapib (ANA) 40 mg
Number of subjects: 589

Group type: COMPARATOR
Intervention: Atorvastatin (ATV) 20 mg with Anacetrapib
Number of subjects: 589
Study: 18652550

Group type: EXPERIMENTAL
Intervention: Intradermal trivalent inactivated influenza vaccine (15 or 21 microg of hemagglutinin per strain)
Number of subjects: 1107

Group type: COMPARATOR
Intervention: Intramuscular control vaccine
Number of subjects: 1107
Study: 16582061

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg daily)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 533
Study: 12709465

Group type: EXPERIMENTAL
Intervention: COER verapamil (180 mg)
Number of subjects: 16602

Group type: COMPARATOR
Intervention: Atenolol (50 mg) or Hydrochlorothiazide (12.5 mg)
Number of subjects: 16602

Group type: EXPERIMENTAL
Intervention: COER verapamil
Number of subjects: 16602

Group type: COMPARATOR
Intervention: Atenolol or Hydrochlorothiazide
Number of subjects: 16602

Group type: EXPERIMENTAL
Intervention: Any prespecified cardiovascular disease-related event
Number of subjects: 16602

Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 16602
Study: 11044869

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 117
Study: 8642189

Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 133
Study: 1421641

Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 140
Study: 3003298

Group type: EXPERIMENTAL
Intervention: Captopril (CAP) 25 mg orally
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Captopril (CAP) + Naloxone (NAL) 0.4 mg bolus followed by 4.0 mg/h infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Naloxone (NAL)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Captopril (CAP)
Number of subjects: 6
Study: 31510831

Group type: EXPERIMENTAL
Intervention: Combined epidural and general anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 0
Study: 29045820

Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil cream
Number of subjects: 601

Group type: COMPARATOR
Intervention: methyl aminolevulinate photodynamic therapy (MAL-PDT)
Number of subjects: 601
Study: 26718237

Group type: EXPERIMENTAL
Intervention: Physiotherapy plus medication
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 24317794

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline triacylglycerol concentrations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline BMI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline visceral adiposity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline subcutaneous adiposity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gly482Ser (rs8192678, PPARGC1A)
Number of subjects: 0
Study: 23090987

Group type: EXPERIMENTAL
Intervention: Dasatinib (100-200 mg daily) + CCNU (90-110 mg/m2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dasatinib + CCNU
Number of subjects: 26
Study: 20606413

Group type: EXPERIMENTAL
Intervention: Continuous erythropoietin receptor activator (CERA) once monthly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epoetin beta therapy
Number of subjects: 0
Study: 17629056

Group type: EXPERIMENTAL
Intervention: Early laparoscopy
Number of subjects: 522

Group type: COMPARATOR
Intervention: Active observation
Number of subjects: 522
Study: 15865068

Group type: EXPERIMENTAL
Intervention: Epirubicin on day 1 followed by paclitaxel on day 2 (sequence A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Paclitaxel on day 1 followed by epirubicin on day 2 (sequence B)
Number of subjects: 46
Study: 12065998

Group type: EXPERIMENTAL
Intervention: Parent visual analogue scale (VAS) ratings
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Child visual analogue scale (VAS) ratings
Number of subjects: 78
Study: 9797618

Group type: EXPERIMENTAL
Intervention: Portage (developmental education programme)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Parent adviser (nondirectional counselling)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Preterm control
Number of subjects: 309
Study: 7644052

Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg qid)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16